Question-and-Answer Session
Operator
(Operator instructions) Our first question comes from the line of Jessica Lee. Please proceed.
Jessica Lee – Goldman Sachs
Thank you for taking my questions. First question with regard to your recent results on XL184 in GBM. So, if I read the data correctly, it looks like for the 125-milligram arm, the discontinuation rates due to AE a 17%, is that correct, and do you think that discontinuation rate is high enough for you to consider a lower dosage?
George Scangos
I think the package of data that we updated at the SNO last week highlights the clear sign of clinical activity we see with XL184 at the 125-milligram in second, third line GBM patients. The safety and tolerability parameters are continuing to be evaluated. The n total number of patients that were discussed at SNO is relatively small. As I mentioned in the script, we are looking very closely at tolerability, at the frequency and duration of interruptions and most importantly the duration of response with 184 at the dose. So, this is all in progress, and we are really focused primarily on expanding that data set. We have also recently amended the protocol to do much more aggressive adverse event management, and much more rapid dose reduction as needed from a standpoint of emerging adverse events to be able to potentially widen that window, and that amendment is now going forward. We are also prepared. As I mentioned in the script as needed to explore either lower doses or alternating dose regimen. So, it’s really a matter of refining and fine-tuning the dose and the manner by which we dose patients in this indication, and I think we are on track to do that pretty well right now.
Jessica Lee – Goldman Sachs
Great, thank you.
George Scangos
You bet.
Operator
Our next question comes from the line of Eric Schmidt. Please proceed.
Eric Schmidt – Cowen & Company
Thanks for taking my question. Just another question on 184 in GBM, I guess for Mike, do you now think there is enough data to suggest that the drug is more active in Avastin na
- To read the full transcript on Seeking Alpha, click here »
